These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 25104633)

  • 1. Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models.
    Keebler D; Revill P; Braithwaite S; Phillips A; Blaser N; Borquez A; Cambiano V; Ciaranello A; Estill J; Gray R; Hill A; Keiser O; Kessler J; Menzies NA; Nucifora KA; Vizcaya LS; Walker S; Welte A; Easterbrook P; Doherty M; Hirnschall G; Hallett TB
    Lancet Glob Health; 2014 Jan; 2(1):e35-43. PubMed ID: 25104633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
    Eaton JW; Menzies NA; Stover J; Cambiano V; Chindelevitch L; Cori A; Hontelez JA; Humair S; Kerr CC; Klein DJ; Mishra S; Mitchell KM; Nichols BE; Vickerman P; Bakker R; Bärnighausen T; Bershteyn A; Bloom DE; Boily MC; Chang ST; Cohen T; Dodd PJ; Fraser C; Gopalappa C; Lundgren J; Martin NK; Mikkelsen E; Mountain E; Pham QD; Pickles M; Phillips A; Platt L; Pretorius C; Prudden HJ; Salomon JA; van de Vijver DA; de Vlas SJ; Wagner BG; White RG; Wilson DP; Zhang L; Blandford J; Meyer-Rath G; Remme M; Revill P; Sangrujee N; Terris-Prestholt F; Doherty M; Shaffer N; Easterbrook PJ; Hirnschall G; Hallett TB
    Lancet Glob Health; 2014 Jan; 2(1):e23-34. PubMed ID: 25104632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study.
    Kahn JG; Marseille E; Moore D; Bunnell R; Were W; Degerman R; Tappero JW; Ekwaru P; Kaharuza F; Mermin J
    BMJ; 2011 Nov; 343():d6884. PubMed ID: 22074713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.
    Boyer S; March L; Kouanfack C; Laborde-Balen G; Marino P; Aghokeng AF; Mpoudi-Ngole E; Koulla-Shiro S; Delaporte E; Carrieri MP; Spire B; Laurent C; Moatti JP;
    Lancet Infect Dis; 2013 Jul; 13(7):577-86. PubMed ID: 23602084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis.
    Smith JA; Sharma M; Levin C; Baeten JM; van Rooyen H; Celum C; Hallett TB; Barnabas RV
    Lancet HIV; 2015 Apr; 2(4):e159-68. PubMed ID: 25844394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of monitoring strategies for antiretroviral therapy of HIV infected patients in resource-limited settings: software tool.
    Estill J; Salazar-Vizcaya L; Blaser N; Egger M; Keiser O
    PLoS One; 2015; 10(3):e0119299. PubMed ID: 25793531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Home testing and counselling to reduce HIV incidence in a generalised epidemic setting: a mathematical modelling analysis.
    Ying R; Sharma M; Celum C; Baeten JM; van Rooyen H; Hughes JP; Garnett G; Barnabas RV
    Lancet HIV; 2016 Jun; 3(6):e275-82. PubMed ID: 27240790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of point-of-care testing with task-shifting for HIV care in South Africa: a modelling study.
    Sharma M; Mudimu E; Simeon K; Bershteyn A; Dorward J; Violette LR; Akullian A; Abdool Karim SS; Celum C; Garrett N; Drain PK
    Lancet HIV; 2021 Apr; 8(4):e216-e224. PubMed ID: 33347810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of point-of-care viral load monitoring of antiretroviral therapy in resource-limited settings: mathematical modelling study.
    Estill J; Egger M; Blaser N; Vizcaya LS; Garone D; Wood R; Campbell J; Hallett TB; Keiser O;
    AIDS; 2013 Jun; 27(9):1483-92. PubMed ID: 23462219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients.
    Kimmel AD; Goldie SJ; Walensky RP; Losina E; Weinstein MC; Paltiel AD; Zhang H; Freedberg KA;
    Antivir Ther; 2005; 10(1):41-52. PubMed ID: 15751762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating strategies to improve HIV care outcomes in Kenya: a modelling study.
    Olney JJ; Braitstein P; Eaton JW; Sang E; Nyambura M; Kimaiyo S; McRobie E; Hogan JW; Hallett TB
    Lancet HIV; 2016 Dec; 3(12):e592-e600. PubMed ID: 27771231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How do different eligibility guidelines for antiretroviral therapy affect the cost-effectiveness of routine viral load testing in sub-Saharan Africa?
    Scott Braithwaite R; Nucifora KA; Toohey C; Kessler J; Uhler LM; Mentor SM; Keebler D; Hallett T
    AIDS; 2014 Jan; 28 Suppl 1(0 1):S73-83. PubMed ID: 24468949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of point-of-care CD4+ and laboratory viral load in tailoring antiretroviral therapy monitoring strategies to resource limitations.
    Hyle EP; Jani IV; Rosettie KL; Wood R; Osher B; Resch S; Pei PP; Maggiore P; Freedberg KA; Peter T; Parker RA; Walensky RP
    AIDS; 2017 Sep; 31(15):2135-2145. PubMed ID: 28906279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies.
    Ouattara EN; Robine M; Eholié SP; MacLean RL; Moh R; Losina E; Gabillard D; Paltiel AD; Danel C; Walensky RP; Anglaret X; Freedberg KA
    Clin Infect Dis; 2016 Jun; 62(11):1454-1462. PubMed ID: 26936666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
    Moeremans K; Hemmett L; Hjelmgren J; Allegri G; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():147-67. PubMed ID: 21182349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe.
    Medina Lara A; Kigozi J; Amurwon J; Muchabaiwa L; Nyanzi Wakaholi B; Mujica Mota RE; Walker AS; Kasirye R; Ssali F; Reid A; Grosskurth H; Babiker AG; Kityo C; Katabira E; Munderi P; Mugyenyi P; Hakim J; Darbyshire J; Gibb DM; Gilks CF;
    PLoS One; 2012; 7(4):e33672. PubMed ID: 22545079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
    Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
    Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis.
    Bendavid E; Young SD; Katzenstein DA; Bayoumi AM; Sanders GD; Owens DK
    Arch Intern Med; 2008 Sep; 168(17):1910-8. PubMed ID: 18809819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings.
    Chang LW; Harris J; Humphreys E
    Cochrane Database Syst Rev; 2010 Apr; (4):CD008494. PubMed ID: 20393969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expanding antiretroviral options in resource-limited settings--a cost-effectiveness analysis.
    Bendavid E; Wood R; Katzenstein DA; Bayoumi AM; Owens DK
    J Acquir Immune Defic Syndr; 2009 Sep; 52(1):106-13. PubMed ID: 19448557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.